VRNA insider: 72,000 RSU shares converted, options settled for cash
Rhea-AI Filing Summary
Verona Pharma plc (VRNA) reported insider changes tied to a takeover transaction effective 10/07/2025. The reporting director, James Aloysius Brady, showed disposal of 23,176 Ordinary Shares and grant/conversion activity that results in ownership of 72,000 Ordinary Shares immediately following the transactions. The filing explains a Scheme of Arrangement under which each Scheme Share received $13.375 in cash and each American Depositary Share (ADS)—representing eight Ordinary Shares—received $107 in cash at the Effective Time. Time‑based RSU awards converted into cash rights covering the equivalent of 72,000 Ordinary Shares, and multiple share options were accelerated and cashed out where in‑the‑money; the filing lists option adjustments affecting 624,000 underlying Ordinary Shares across three strike prices.
Positive
- RSUs covering 72,000 Ordinary Shares were converted into cash at $107 per ADS, providing liquidity to the holder
- In‑the‑money options were accelerated and settled for cash, avoiding exercise cash outlay for the reporting person
Negative
- Director disposed 23,176 Ordinary Shares in connection with the Scheme of Arrangement, reducing direct shareholdings
- All listed options and RSUs were converted to cash, eliminating potential future equity upside for the reporting person
Insights
TL;DR: Director holdings converted and cashed out under a takeover; RSUs and options settled for cash at specified consideration.
The transactions are execution steps of a Scheme of Arrangement where each ADS received $107 in cash at the Effective Time, so equity awards (RSUs and in‑the‑money options) were accelerated and converted into cash payments per the Transaction Agreement. This explains the reported disposals and the new reported beneficial ownership numbers immediately after the Effective Time.
Dependencies include the stated Transaction Agreement and the specified ADS consideration; tax withholding and mechanic details determine net cash to the reporting person. Monitor any supplemental filings that show actual cash amounts received or tax withholdings within the next reporting cycle.
TL;DR: Time‑based RSUs vested and converted to cash; option treatment depended on strike vs. ADS consideration.
Per the agreement, outstanding time‑based RSUs covering 72,000 Ordinary Shares were treated as vested and converted into cash equal to ADS count times the ADS Consideration. Options with exercise prices below the ADS Consideration were converted into cash equal to the difference between $107 per ADS and the option strike, multiplied by underlying ADSs.
Key items to watch are any post‑closing tax withholdings and the final cash settlement statements; these will determine net proceeds and are typically resolved within weeks after closing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 288,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 240,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 23,176 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
